Latest News

The FDA describes the RDEA pilot program as a program to support novel endpoint efficacy development for drugs that treat rare diseases.

Emerging pharmacological and optical strategies are shaping a new era.

The Polaris platform is the world’s first AI-supported and robotics-enabled surgical system developed specifically for ophthalmology, according to the company.

EYDENZELT is Celltrion's first FDA-approved biologic product in ophthalmology.

Singh highlights how understanding the “why” behind diagnostics and procedures boosts technician confidence, fosters pride, and strengthens their role in patient care.

A recent study uncovers a novel biomarker for retinal vascular diseases, highlighting the significance of intermittent capillary perfusion in monitoring treatment efficacy.

The video-driven platform equips ophthalmic practices with tools to standardize education, improve workflow, and foster technician engagement.

Sura-vec is intended to be a potential 1-time treatment consisting of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF).

Maximizing treatment based on GA location, lesion progression, and morphologic retinal changes.

Join the American Academy of Ophthalmology's annual meeting for cutting-edge insights, networking, and engaging events from October 17-20 in Orlando.

The company can now initiate the Opti-GAIN (Optimized Geographic Atrophy INterventional) phase 1/2 clinical trial.

Real-world insights emphasize identifying underlying causes to tailor treatment.

Both have issued further statements regarding the deal.